Fusion pharmaceuticals and bwxt medical announce actinium-225 partnership to scale supply for developing targeted alpha therapies

-  agreement augments fusion's existing isotope supply as pipeline of clinical stage actinium-based radiopharmaceuticals grows -  furthers bwxt medical's position as a global leader in medical isotope supply hamilton, on , jan. 5, 2023 /prnewswire/ -- fusion pharmaceuticals inc. (nasdaq: fusn), and bwxt medical ltd., a subsidiary of bwx technologies, inc. (nyse: bwxt), today announced that the companies have entered into a preferred partner agreement for the supply of actinium-225.
BWXT Ratings Summary
BWXT Quant Ranking